To the Editor: Mohs micrographic surgery (MMS) has been reported to be safe, with a low incidence of adverse effects both intraoperatively and postoperatively.
1 Approximately 25% to 38% of patients who undergo cutaneous surgery are taking an antithrombotic agent that puts them at a slightly higher risk for bleeding. 2 Novel oral anticoagulants (NOACs) are an increasing presence in the dermatologist's office, as head-to-head clinical trials have shown them to have efficacy equal to superior that of warfarin. 3 A retrospective chart review was performed of all patients who underwent MMS at the University of Cincinnati between October 1, 2011, and September 15, 2016, while they were taking any of the NOACs dabigatran, apixaban, or rivaroxaban. Data regarding age, sex, dose of anticoagulant medication, indication, concurrent anticoagulation, surgical site, number of stages, repair type, and complications (Table I) were collected. All patients were contacted by the surgeon and queried regarding complications at the routine 48-hour follow-up call. This study protocol was approved by the University of Cincinnati Institutional Review Board.
Fifty-one patients who were taking dabigatran, apixaban, or rivaroxaban underwent 76 MMS procedures, with only 1 mild bleeding complication in a patient who was taking rivaroxaban and 2 cases of infection in which both patients were taking dabigatran.
The overall rate of complications (Table II) in patients taking NOACs was very low at 3.94% (3 of 76). The hemorrhagic complication rate was calculated as 1.3% (1 of 76). The patient experienced mild intermittent bleeding for 10 hours after surgery that was controlled with application of direct pressure for 20 minutes. The overall infection rate was 2.6% (2 of 76). Both patients called within 1 week of the procedure complaining of erythema, discharge, and crusting that aroused concern for infection and were presumptively given cephalexin, 500 mg 3 times a day for 7 days, with no further complications. No patient required intravenous antibiotics or inpatient admission.
Current guidelines recommend continuing warfarin, clopidogrel, and aspirin during cutaneous surgery. 4 These recommendations have been extrapolated to NOACs. The rationale for this is based on data from several peer-reviewed studies showing that the risk of hemorrhagic complications, dehiscence, or infection was not increased in patients taking anticoagulants compared with in controls. 1, 4 Likewise, our findings did not show a significant difference in the rate of complications in patients taking NOACs compared with in all other patients who underwent MMS during the same period at this institution. The bleeding complication rate was 1.3% for patients receiving NOACs versus 0.7% for all other patients, and the infection rates were 2.6% and 1.1% respectively. A larger cohort of patients receiving NOACs is needed to confirm these findings.
Furthermore, temporary discontinuation of anticoagulants has not been shown to reduce the risk for hemorrhagic complications compared with in controls or in those who continued to take them. 1, 3, 4 Continuing the use of warfarin and NOACs to avoid potentially lethal thromboembolic complications is considered the most appropriate option. [1] [2] [3] [4] Although there are no previous data 4, 5 Although many studies have examined the prevalence of individual tanning modalities, little is known about how people combine tanning modalities. Combination tanning may be associated with higher cumulative UV exposure than single-modality tanning and, therefore, higher risk for skin cancer. Interventions focusing on a single modality without acknowledging sequential or concurrent use of other tanning modalities may not effectively reduce total UV exposure. The purpose of this study was to determine the prevalence of combination tanning among undergraduates at a southeastern university and identify characteristics distinguishing combination tanners from singlemodality tanners.
Surveys were e-mailed to all undergraduates at a public state university in Alabama in March 2016. This survey had previously been approved by the University of South Alabama Institutional Review Board (protocol number #854018-1). Primary outcome measures were self-reported current OT and/or ever use of (1) IT and/or (2) spray tanning [ST ] . Combination tanners were defined by use of 2 or more tanning modalities. Descriptive measures included demographics, Fitzpatrick skin type, attitudinal variables, and risk perceptions. Logistic and stepwise regressions were used to examine relationships between descriptive measures and tanning behaviors.
Of the 2587 respondents (25% response rate), 1942 reported at least 1 tanning behavior, thus comprising the study population. The majority were female (73.2%), white (80.0%), and residents of Alabama (78.5%). Use of only 1 tanning modality was reported by 726 respondents (37.3% [termed single-modality tanners]), whereas 1216 respondents reported using/having used more than 1 tanning modality (62.7% [termed combination tanners]) (Fig 1) . Among combination tanners, OT plus IT were used by 667 (54.9%), with OT plus IT plus ST used by 444 (36.5%). Therefore, both UV-based tanning modalities (OT 1 IT), with or without ST, were used by 91.4% of combination tanners.
In the multivariate analysis (Table I) , females were more than 3 times as likely as males to be 
